米托蒽醌联合长春新碱、环磷酰胺和氟尿嘧啶治疗晚期乳腺癌。
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
作者信息
Metz R, Delgado M, Keiling R, Cappelaere P, Armand J P, Prevot G, Misset J L, Grimbert J, Mathe G
出版信息
Invest New Drugs. 1985;3(2):163-6. doi: 10.1007/BF00174164.
In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose. After the EORTC Clinical Screening Group phase II trial we have conducted an "expected difference method" comparative phase II trial using the combination DOX, VCR, CPM, FU and the combination of MTX (10mg/m2), VCR, CPM and FU on a population of 50 breast carcinoma patients similar to those taking part in the first study. The reasons for similarity of action will be presented and discussed.
在我们运用化疗治疗晚期乳腺癌的丰富经验中，阿霉素（DOX）、长春新碱（VCR）、环磷酰胺（CPM）和氟尿嘧啶（FU）联合使用时，完全缓解加部分缓解率超过60%，脱发率达100%，且根据总剂量不同，心脏毒性频发。在欧洲癌症研究与治疗组织（EORTC）临床筛查小组的II期试验之后，我们采用“预期差异法”进行了一项II期对比试验，对50名与参与第一项研究的患者相似的乳腺癌患者，使用DOX、VCR、CPM、FU联合方案以及甲氨蝶呤（MTX，10mg/m²）、VCR、CPM和FU联合方案。我们将阐述并讨论作用相似性的原因。
Zotero 插件